Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Morgan Stanley 23rd

Michael Ulz
Equity Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I’m Michael Ulz, one of the biotech analysts here, and it’s my pleasure to introduce Jeff Poulton, CFO of Alnylam Pharmaceuticals. Before we get started, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. And with that, Jeff, thanks for sharing your time with us today. We really appreciate it. And maybe to kick things off, if you can just give a brief introduction to Alnylam and then we can hop into some Q&A.

Jeffrey Poulton
CFO & Executive VP

Great. Thanks for hosting and having us here today. I’m at Alnylam and Alnylam is a company that’s developed a new class of medicines based on Nobel Prize-winning science, RNAi or RNA interference. And it’s been about a 25-year journey for the company. I would say the first 15 years were really around particularly on delivery, figuring out how to get the medicines to the right parts of the body and in the right cells in the body. And once that was figured out, things really started to change for the company. And the way the company is positioned today is there’s 6 products that are in the market that were discovered in Alnylam’s labs. 4 of those products are being marketed and sold by the company on our own. The other 2 are through partners. We’ve got a pipeline of 20-plus medicines in the clinic, all